


## CLAIMS:-

1 A compound of the general formula



5 or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

A is selected from O, S, NR<sub>1</sub>, where R<sub>1</sub> is selected from H, C<sub>1-4</sub> alkyl;

B is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C<sub>1-4</sub> alkyl, CF<sub>3</sub>, CN, aryl, hetaryl, OH, OCF<sub>3</sub>, OC<sub>1-4</sub>alkyl, OC<sub>2-6</sub>alkylNR<sub>2</sub>R<sub>3</sub>, Oaryl, Ohetaryl, CO<sub>2</sub>R<sub>2</sub>, CONR<sub>2</sub>R<sub>3</sub>, NR<sub>2</sub>R<sub>3</sub>, C<sub>1-4</sub> alkylNR<sub>2</sub>R<sub>3</sub>, NR<sub>4</sub>C<sub>1-4</sub>alkylNR<sub>2</sub>R<sub>3</sub>, NR<sub>2</sub>COR<sub>3</sub>, OC(O)NR<sub>2</sub>R<sub>3</sub>, NR<sub>4</sub>CONR<sub>2</sub>R<sub>3</sub>, NR<sub>2</sub>SO<sub>2</sub>R<sub>3</sub>; and R<sub>2</sub>, R<sub>3</sub> are each independently H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl heterocyclyl, aryl, hetaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub> alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR<sub>5</sub>; and R<sub>4</sub> is selected from H, C<sub>1-4</sub> alkyl; and R<sub>5</sub> is selected from H, C<sub>1-4</sub> alkyl;

Q is a bond, or C<sub>1-4</sub> alkyl;


W is selected from H, C<sub>1-4</sub>alkyl, C<sub>2-6</sub>alkenyl; where C<sub>1-4</sub>alkyl or C<sub>2-6</sub>alkenyl may be optionally substituted with C<sub>1-4</sub>alkyl, OH, OC<sub>1-4</sub>alkyl, NR<sub>6</sub>C(O)R<sub>7</sub>, CONR<sub>6</sub>R<sub>7</sub>, OR<sub>6</sub>, NR<sub>6</sub>R<sub>7</sub>; and R<sub>6</sub>, and R<sub>7</sub> are each independently H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl cycloalkyl, C<sub>1-4</sub> alkyl heterocyclyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR<sub>8</sub> and R<sub>8</sub> is selected from H, C<sub>1-4</sub> alkyl;

Y is H, aryl or hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C<sub>1-4</sub> alkyl, CF<sub>3</sub>, aryl, hetaryl, OH, OCF<sub>3</sub>, CN, C<sub>2-4</sub> alkynyl, OC<sub>1-4</sub>alkyl, OC<sub>2-6</sub>alkylNR<sub>9</sub>R<sub>10</sub>, Oaryl, Ohetaryl, CO<sub>2</sub>R<sub>9</sub>, CONR<sub>9</sub>R<sub>10</sub>, NR<sub>9</sub>R<sub>10</sub>, C<sub>1-4</sub> alkylNR<sub>9</sub>R<sub>10</sub>,

BEST AVAILABLE COPY

NR11C<sub>1-4</sub>alkylNR9R10, NR9COR10, NR11CONR9R10, NR9SO<sub>2</sub>R10; and R9, R10 are each independently H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl heterocyclyl, aryl, hetaryl, C<sub>1-4</sub> alkyl aryl, C<sub>1-4</sub> alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR12; and R11 is selected from H, C<sub>1-4</sub> alkyl; and  
 5 R12 is selected from H, C<sub>1-4</sub> alkyl.

2. A compound according to claim 1 of the general formula II:



II

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or  
 10 diastereomers thereof, wherein:

R1 is selected from H, C<sub>1-4</sub> alkyl;







B is aryl, hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C<sub>1-4</sub> alkyl, CF<sub>3</sub>, aryl, hetaryl, OH, OCF<sub>3</sub>, OC<sub>1-4</sub>alkyl, OC<sub>2-5</sub>alkylNR2R3, Oaryl, Ohetaryl, CO<sub>2</sub>R2, CONR2R3, NR2R3, C<sub>1-4</sub> alkylNR2R3, NR4C<sub>1-4</sub>alkylNR2R3,  
 15 NR2COR3, NR4CONR2R3, NR2SO<sub>2</sub>R3; and R2, R3 are each independently H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl heterocyclyl, aryl, hetaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub> alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR5; and R4 is selected from H, C<sub>1-4</sub> alkyl; and R5 is selected from H, C<sub>1-4</sub> alkyl;

20 Q is a bond, or C<sub>1-4</sub> alkyl;


W is selected from H, C<sub>1-4</sub>alkyl, C<sub>2-6</sub>alkenyl; where C<sub>1-4</sub>alkyl or C<sub>2-6</sub>alkenyl may be optionally substituted with C<sub>1-4</sub>alkyl, OH, OC<sub>1-4</sub>alkyl, NR6R7; and R6, and R7 are each independently H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl cycloalkyl, C<sub>1-4</sub> alkyl heterocyclyl, aryl, hetaryl, or may be joined to form an optionally substituted 3-8 membered ring  
 25 optionally containing an atom selected from O, S, NR8 and R8 is selected from H, C<sub>1-4</sub> alkyl;

Y is H, aryl or hetaryl optionally substituted with 0-3 substituents independently chosen from halogen, C<sub>1-4</sub> alkyl, CF<sub>3</sub>, aryl, hetaryl, OH, OCF<sub>3</sub>, OC<sub>1-4</sub>alkyl, OC<sub>2-5</sub>alkylNR<sub>9</sub>R<sub>10</sub>, Oaryl, Ohetaryl, CO<sub>2</sub>R<sub>9</sub>, CONR<sub>9</sub>R<sub>10</sub>, NR<sub>9</sub>R<sub>10</sub>, C<sub>1-4</sub>alkylNR<sub>9</sub>R<sub>10</sub>, NR<sub>11</sub>C<sub>1-4</sub>alkylNR<sub>9</sub>R<sub>10</sub>, NR<sub>9</sub>COR<sub>10</sub>, NR<sub>11</sub>CONR<sub>9</sub>R<sub>10</sub>, NR<sub>9</sub>SO<sub>2</sub>R<sub>10</sub>; and R<sub>9</sub>, R<sub>10</sub> are each independently H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl heterocyclyl, aryl, hetaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub> alkyl hetaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR<sub>12</sub>; and R<sub>11</sub> is selected from H, C<sub>1-4</sub> alkyl; and R<sub>12</sub> is selected from H, C<sub>1-4</sub> alkyl.


3. A compound according to claim 1 wherein the compound is selected from the group consisting of:

C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub>C<sub>23</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>4</sub>C<sub>20</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>C<sub>22</sub>H<sub>20</sub>ClFN<sub>2</sub>O<sub>4</sub>C<sub>19</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub>C<sub>22</sub>H<sub>20</sub>ClFN<sub>2</sub>O<sub>4</sub>


62




C19H16N2O2



C22H21ClN2O4




C20H18N3O2




C20H16N2O3

5




C23H24N2O4




C16H12N2OS

10




C19H18N2O3




C13H14N2OS

15




C22H22N2O2




C18H16N2OS

63




C21H19FN2O2




C20H19N3O2S

5




C21H19FN2O2




C18H16N2O6

10




C21H20N2O2




C17H13FN2O5

15




C17H13FN2O5




C21H20N2O2

20







C18H16N2O5





C21H20N2O2

64



5



10




15




20

65




C19H17N3O2




C20H18N2O2

5




C19H16N2O2




C21H20N2O3

10




C22H22N2O4




C20H17FN2O3

15




C18H16N2O3




C20H17FN2O3

20



C21H20N2O3



C20H18N2O3

4. A composition comprising a carrier and at least one compound of any one of claims 1 to 3.
5. A composition comprising a carrier and at least one compound of any one of claims 1 to 4.
- 5 6. A method of treating a tyrosine kinase-associated disease state in a subject, the method comprising administering a therapeutically effective amount of at least one compound of any one of claims 1 to 4 or a therapeutically effective amount of a composition of claim 5.
7. A method according to claim 6 wherein the disease state is selected from the group  
10 consisting of Atopy, such as Allergic Asthma, Atopic Dermatitis (Eczema), and Allergic Rhinitis; Cell Mediated Hypersensitivity, such as Allergic Contact Dermatitis and Hypersensitivity Pneumonitis; Rheumatic Diseases, such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, Juvenile Arthritis, Sjögren's Syndrome, Scleroderma, Polymyositis, Ankylosing Spondylitis, Psoriatic  
15 Arthritis; Other autoimmune diseases such as Type I diabetes, autoimmune thyroid disorders, and Alzheimer's disease; Viral Diseases, such as Epstein Barr Virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1, Varicella-Zoster Virus (VZV), Human Papilloma Virus (HPV); Cancer, such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,  
20 endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary  
25 adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma,  
30 pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma, and carcinomas forming from tissue of the breast, prostate, kidney, bladder or colon, and neoplastic



disorders arising in adipose tissue, such as adipose cell tumors, e.g., lipomas, fibrolipomas, lipoblastomas, lipomatosis, hibernomas, hemangiomas and/or liposarcomas.

- 5      8.      The use of at least one of the compounds of any one of claims 1 to 4 in the preparation of a medicament for the treatment of a tyrosine kinase-associated disease state.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**